中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2008年
18期
4-6
,共3页
白桦%申维玺%窦永充%张彦舫%郑瑾%郑涛%叶建增%徐敏
白樺%申維璽%竇永充%張彥舫%鄭瑾%鄭濤%葉建增%徐敏
백화%신유새%두영충%장언방%정근%정도%협건증%서민
肝肿瘤%高频透热%肝动脉化疗栓塞
肝腫瘤%高頻透熱%肝動脈化療栓塞
간종류%고빈투열%간동맥화료전새
Liver neoplasms%RF transparent heating%Transcatheter hepatic arterial chemoembolization
目的 观察高频透热联合肝动脉化疗栓塞治疗晚期原发性肝癌的疗效及不良反应.方法 随机将69例晚期原发性肝癌患者分为两组:对照组35例,单纯行动脉化疗栓塞治疗,从导管注入顺铂80mg,氟尿嘧啶1000mg,表阿霉素60mg,其中将表阿霉素与碘化油10ml混合乳化后行栓塞.治疗组34例,行动脉化疗栓塞治疗后再行局部高频透热治疗.结果 治疗组近期疗效总有效率为70.59%,对照组为45.71%,两组比较差异有统计学意义.治疗组0.5、1.0、1.5、2.0年生存率分别为82.35%、73.53%、58.82%、38.24%,对照组分别为74.29%、75.14%、45.71%、22.86%,治疗组有增高的趋势.两组不良反应相近.结论 高频透热联合肝动脉化疗栓塞治疗晚期原发性肝癌优于单纯肝动脉化疗栓塞,且不增加不良反应,是一种安全、有效的综合治疗方法.
目的 觀察高頻透熱聯閤肝動脈化療栓塞治療晚期原髮性肝癌的療效及不良反應.方法 隨機將69例晚期原髮性肝癌患者分為兩組:對照組35例,單純行動脈化療栓塞治療,從導管註入順鉑80mg,氟尿嘧啶1000mg,錶阿黴素60mg,其中將錶阿黴素與碘化油10ml混閤乳化後行栓塞.治療組34例,行動脈化療栓塞治療後再行跼部高頻透熱治療.結果 治療組近期療效總有效率為70.59%,對照組為45.71%,兩組比較差異有統計學意義.治療組0.5、1.0、1.5、2.0年生存率分彆為82.35%、73.53%、58.82%、38.24%,對照組分彆為74.29%、75.14%、45.71%、22.86%,治療組有增高的趨勢.兩組不良反應相近.結論 高頻透熱聯閤肝動脈化療栓塞治療晚期原髮性肝癌優于單純肝動脈化療栓塞,且不增加不良反應,是一種安全、有效的綜閤治療方法.
목적 관찰고빈투열연합간동맥화료전새치료만기원발성간암적료효급불량반응.방법 수궤장69례만기원발성간암환자분위량조:대조조35례,단순행동맥화료전새치료,종도관주입순박80mg,불뇨밀정1000mg,표아매소60mg,기중장표아매소여전화유10ml혼합유화후행전새.치료조34례,행동맥화료전새치료후재행국부고빈투열치료.결과 치료조근기료효총유효솔위70.59%,대조조위45.71%,량조비교차이유통계학의의.치료조0.5、1.0、1.5、2.0년생존솔분별위82.35%、73.53%、58.82%、38.24%,대조조분별위74.29%、75.14%、45.71%、22.86%,치료조유증고적추세.량조불량반응상근.결론 고빈투열연합간동맥화료전새치료만기원발성간암우우단순간동맥화료전새,차불증가불량반응,시일충안전、유효적종합치료방법.
Objective To observe the efficacy and toxicities of RF transparent heating (RTH) combined with transcatheter hepatic arterial chemoembolization (TACE) in the treatment of advanced primary hepatic carcinoma. Methods In a randomized manner, 69 patients with advanced primary hepatic carcinoma were divided into two groups: study group (TACE+RTH) 34 cases and control group (TACE alone) 35 cases, the control group were treated with DDP 80mg, FU 1000mg and E-ADM 60mg, E-ADM was used with iodized oil embolism 10ml. Results The total effective rate in the near future were 70.59% and 45.71%, the overall survival rates of 0.5, 1.0, 1.5, 2.0 years were 82.35%, 73.53%, 58.82%, 38.24% in study group and 74.29%, 75.14%, 45.71%, 22.86% in control group, respectively. Toxicities were similar comparing with the two groups. Conclusions RTH combined with TACE in the treatment of advanced primary hepatic carcinoma is better than TACE alone, at the same time TACE +RTH method is no increasing toxicity and is an effective safe combined one.